[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650699":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":50,"collaborators":20,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-MY6349 PET\u002FCT","EXPERIMENTAL","Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET\u002FCT imaging within the specified time.",[13],"Diagnostic Test: Compared the diagnostic performance of 68Ga-MY6349 PET\u002FCT with 68Ga-FAPI PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Compared the diagnostic performance of 68Ga-MY6349 PET\u002FCT with 68Ga-FAPI PET\u002FCT","Each subject receives a single intravenous injection of 68Ga-MY6349 and 68Ga-FAPI and undergoes PET\u002FCT imaging within the specified time. For participants who were not radioiodine-refractory or who did not have MTC or ATC, DxWBS was conducted. Each participant received an intramuscular injection of rhTSH on two consecutive days, followed by the oral administration of 131I. DxWBS was performed 2 days after 131I administration",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Haojun Chen, MD, PhD","CONTACT","18659285282","leochen0821@foxmail.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Hao Fu, MD, PhD","15959230059","fuhaonuclear@163.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000","RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":41,"coordinates":42},"Point",[43,44],118.08187,24.47979,{"lat":44,"lon":43},[47,49],{"name":23,"role":24,"phone":48,"phoneExt":20,"email":26},"86-592-2137077",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"type":51,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100650699","trophoblast-cell-surface-antigen-2-trop-2-targeted-petct-in-recurrent-and-metastatic-thyroid-cancer-100650699",false,"NCT07753499","Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET\u002FCT in Recurrent and Metastatic Thyroid Cancer","Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET\u002FCT in Recurrent and Metastatic Thyroid Cancer and Compared With 68Ga-FAPI PET\u002FCT","Inclusion Criteria:\n\n* Adult patients (aged 18 years or older);\n* Patients with a history of previously treated thyroid cancer, including DTC and HGFCTC following thyroidectomy with or without 131I therapy, MTC after thyroidectomy, or ATC; either (1) evidence of structural or suspicious lesions on standard of care imaging or (2) biochemical evidence of disease in the absence of structural findings, defined as elevated thyrotropin suppressed thyroglobulin (Tgon ≥1 ng\u002FmL after 131I ablation or ≥5 ng\u002FmL without ablation) with negative anti thyroglobulin antibodies (\\\u003C20 IU\u002FmL) for DTC and HGFCTC or elevated calcitonin (\\>10 pg\u002FmL) for MTC;\n* Patients who had scheduled both 68Ga-MY6349 and 68Ga-FAPI PET\u002FCT scans;\n* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n* No other anticancer therapy within four weeks prior to PET imaging.\n\nExclusion Criteria:\n\n* Pregnant or lactating patients;\n* Patients with a second primary tumor;\n* The inability or unwillingness of the research participant, parent, or legal representative to provide written informed consent.","ALL","18 Years","90 Years",{"count":63,"type":64},120,"ESTIMATED","INTERVENTIONAL",[67],"NA","In this study, we comprehensively evaluated the clinical utility of Trop2 PET\u002FCT (68Ga-MY6349 PET\u002FCT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET\u002FCT. The primary objective of this study was to evaluate the patient-based sensitivity of 68Ga-MY6349 PET\u002FCT in detecting recurrent and metastatic thyroid cancer. The secondary objectives included its overall specificity, lesion-based diagnostic performance, comparative tumor uptake relative to 68Ga-FAPI PET\u002FCT, and the impact on clinical management.",[70,71,72],"Tumor","Solid Tumor","Thyroid Cancer",[70,74,75,76,77,78,79],"Thyroid cancer","TENIS","Trop-2","FAP","Diagnosis","PET\u002FCT","2026-08-04",{"date":82,"type":83},"2026-08-07","ACTUAL",{"date":85,"type":64},"2026-08-01",{"date":87,"type":64},"2027-12-31",{"name":5,"class":6},1]